Prot#CCFZ533A2202: A 12-month, Open-label, Multicenter, Randomized, Safety, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Two Regimens of Anti-CD40 Monoclonal Antibody,CFZ533 vs. Standard of Care Control, in Adult De Novo Liver Transpla

Project: Research project

Project Details

StatusActive
Effective start/end date4/1/198/31/23

Funding

  • Novartis Pharmaceuticals Corporation (CCFZ533A2202)